Cargando…
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
OBJECTIVE: To assess satisfaction with the serum-free formulation of subcutaneous (sc) interferon (IFN) beta-1a among patients with relapsing multiple sclerosis (MS). METHODS: Patients with relapsing MS who had been receiving sc IFN beta-1a for at least 6 months, were transitioned to the new formula...
Autores principales: | Camu, William, Hadjout, Karim, Latour, Sabine, Pöhlau, Dieter, Masri, Said |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875722/ https://www.ncbi.nlm.nih.gov/pubmed/20517473 |
Ejemplares similares
-
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
por: Devonshire, Virginia, et al.
Publicado: (2010) -
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
por: Singer, Barry, et al.
Publicado: (2012) -
IN VITRO ASSESSMENT OF THE BIOLOGIC ACTIVITY OF INTERFERON BETA FORMULATIONS USED FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
por: Scagnolari, Carolina, et al.
Publicado: (2014) -
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
por: Dwyer, Michael G., et al.
Publicado: (2015) -
A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
por: Jaber, Amer, et al.
Publicado: (2008)